中文名 | CZC-54252 |
英文名 | CZC-54252 |
别名 | 化合物CZC-54252 N-(2-((5-氯-2-((2-甲氧基-4-吗啉苯基)氨基)嘧啶-4-基)氨基)苯基)甲磺酸 |
英文别名 | CS-1730 CZC54252 CZC 54252 CZC-54252 CZC 54252 hydrochloride N-(2-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-ylamino)phenyl)methanesulfonamide Methanesulfonamide, N-[2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- N-[2-[[5-Chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]methanesulfonamide hydrochloride |
CAS | 1191911-27-9 |
化学式 | C22H25ClN6O4S |
分子量 | 504.99 |
密度 | 1.452±0.06 g/cm3(Predicted) |
沸点 | 718.1±70.0 °C(Predicted) |
溶解度 | DMSO: 21 mg/mL |
酸度系数 | 8.50±0.10(Predicted) |
存储条件 | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
体外研究 | CZC-54252 inhibits the activity of recombinant human wild-type LRRK2 with an IC 50 ranging from ~1 to ~5 nM. The G2019S mutant is inhibited with an IC 50 ranging from ~2 to ~7 nM in a TF-FRET assay. In addition, they are screened against a kinase panel of 185 kinases and exhibited good selectivity. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 with an EC 50 of ~1 nM and fully reversed to wild-type levels by CZC-54252 at concentration of 1.6 nM. |
上游原料 | 甲基磺酰氯 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.98 ml | 9.901 ml | 19.802 ml |
5 mM | 0.396 ml | 1.98 ml | 3.96 ml |
10 mM | 0.198 ml | 0.99 ml | 1.98 ml |
5 mM | 0.04 ml | 0.198 ml | 0.396 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!